Testing D-2570 for non-segmental vitiligo
Part of Skin clinical trials.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-segmental vitiligo (white patches in random areas, not one-sided) confirmed by a doctor
- Your vitiligo affects at least 5% of your total body surface area and shows visible signs
- You are between 18 and 65 years old
- If you can become pregnant, you must use effective birth control during the trial and for 30 days after
- You do not have active infections, severe immune problems, or uncontrolled chronic diseases like heart disease or thyroid problems
- You have not had cancer in the past 5 years (skin cancer and cervical precancer are OK)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This trial tests an oral medication (a tablet) for treating non-segmental vitiligo, a condition where white patches appear on the skin. The goal is to see if the drug can safely help bring color back to those patches.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
This trial tests a new medicine called GR2301, given as an injection, combined with light therapy, to see if it can help people with vitiligo. It aims to improve skin color in affected areas, especially on the face.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.